FPT-SOFTWARE
5.8.2024 09:31:33 CEST | Business Wire | Press release
Global technology company FPT Software, a subsidiary of FPT Corporation, and KITZ Corporation, a world-leading manufacturer of industrial valves and fluid control products, recently signed a strategic partnership agreement. The collaboration leverages FPT Software’s scalable workforce and robust expertise to accelerate the digital transformation initiatives across KITZ’s manufacturing and business operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240804936324/en/
The signing ceremony took place in Tokyo, Japan, with KITZ Corporation CEO Makoto Kohno, FPT Corporation EVP and FPT Software CEO Pham Minh Tuan, and senior executives from both sides. (Photo: Business Wire)
Under the agreement, FPT Software will provide digital solutions to enhance KITZ’s product development and design, global supply chain, maintenance services, and sales and marketing activities. FPT Software will also enhance KITZ’s IT infrastructure through cutting-edge, AI-infused solutions to facilitate its operation and manufacturing with greater precision, efficiency, and safety.
“Driving agility, scalability, and enhanced productivity for our clients has always been FPT Software’s priority. With two decades of experience accompanying industry giants in Japan, a diversified delivery network, and a high-quality workforce globally, we are confident to help KITZ streamline operations and improve time-to-market to stay ahead of the rapidly changing manufacturing landscape,” said Pham Minh Tuan, FPT Corporation Executive Vice President and FPT Software Chief Executive Officer.
"I believe that forming a strategic partnership with FPT, a company that provides the latest technologies and services in the digital field, is a significant step forward. We are currently constructing a factory in Vinh Phuc Province, Vietnam, to manufacture and sell stainless steel valves, which are expected to be in high demand in the future, and a factory to produce high-purity gas valves for the semiconductor equipment market. In Vietnam, which is experiencing remarkable growth, we will continue to provide products and services tailored to our customers' markets and regions by partnering with FPT, a global company that has been at the forefront of DX initiatives for many companies,” said Makoto Kohno, KITZ Corporation Chief Executive Officer.
With nearly 20 years in Japan, FPT Software has become one of the largest foreign technology firms in terms of workforce, with 3,500 employees across 17 local offices and innovation hubs, as well as 15,000 global employees dedicated to the Japanese market. The company has provided services and solutions to over 450 clients worldwide, supporting their digital transformation through strategic consulting services and advanced technological solutions such as AI, machine learning, and cloud computing. The IT firm also plays a significant role in promoting technology cooperation and development between Vietnam and Japan, notably an active member of the Japan Business Federation (Keidanren) and the chair of the Vietnam Association of Digital Transformation in Japan (VADX Japan).
Manufacturing is among FPT Software's key domains. It provides comprehensive strategies and execution processes for digital factories on a global scale, leveraging its deep expertise and wide skills network to deliver complex end-to-end projects that enhance manufacturing operations. These proven competencies and success place FPT Software as a leader and disruptor in manufacturing services by IDC MarketScape and HFS Horizons.
About FPT Software
FPT Software, a subsidiary of FPT Corporation, is a global technology and IT services provider headquartered in Vietnam, with $1 billion in revenue (2023) and over 30,000 employees in 30 countries.
The company champions complex business opportunities and challenges with its world-class services in Advanced Analytics, AI, Digital Platforms, Cloud, Hyperautomation, IoT, Low-code, and so on. It has partnered with over 1,100 clients worldwide, nearly 100 of which are Fortune Global 500 companies in Aviation, Automotive, Banking, Financial Services and Insurance, Healthcare, Logistics, Manufacturing, Utilities, and more. For more information, please visit https://fptsoftware.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240804936324/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom